ReviewInternational journal of endocrinology2014
MicroRNAs in Diabetic Kidney Disease.
Review in International journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Predicting rapid decline in kidney function among type 2 diabetes patients: A machine learning approach.Heliyon · 2025Article
- The Potential Biotherapeutic Targets of Contrast-Induced Acute Kidney Injury.International journal of molecular sciences · 2023Review
- Monocyte miRNAs Are Associated With Type 2 Diabetes.Diabetes · 2022Article
- GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy.Expert reviews in molecular medicine · 2021Review
- SMADS-Mediate Molecular Mechanisms in Sjögren's Syndrome.International journal of molecular sciences · 2021Review
- Parallel Multi-Omics in High-Risk Subjects for the Identification of Integrated Biomarker Signatures of Type 1 Diabetes.Biomolecules · 2021Article
- Epigenetics and Inflammation in Diabetic Nephropathy.Frontiers in physiology · 2021Review
- Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.Frontiers in pharmacology · 2020Review
- Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients.Non-coding RNA · 2019Article
- MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury.Annals of translational medicine · 2019Article
- Dicer deficiency in proximal tubules exacerbates renal injury and tubulointerstitial fibrosis and upregulates Smad2/3.American journal of physiology. Renal physiology · 2018Article
- Biogenesis, Stabilization, and Transport of microRNAs in Kidney Health and Disease.Non-coding RNA · 2018Review
- Anabolic Androgenic Steroids: Searching New Molecular Biomarkers.Frontiers in pharmacology · 2018Review
- Alpinia oxyphylla Miq. extract changes miRNA expression profiles in db-/db- mouse kidney.Biological research · 2017Article
- Pathological Effects of Exosomes in Mediating Diabetic Cardiomyopathy.Advances in experimental medicine and biology · 2017Review
- Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.BioMed research international · 2017Article
- Clinical predictive factors in diabetic kidney disease progression.Journal of diabetes investigation · 2017Review
- Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy.Journal of the American Society of Nephrology : JASN · 2016Article
- High glucose enhances microRNA-26a to activate mTORC1 for mesangial cell hypertrophy and matrix protein expression.Cellular signalling · 2015Article
- MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid growth of diabetes and diabetic kidney disease exerts a great burden on society. Owing to the lack of effective treatments for diabetic kidney disease, treatment relies on drugs that either reduces its progression or involve renal replacement therapies, such as dialysis and kidney transplantation. It is urgent to search for biomarkers for early diagnosis and effective therapy. The discovery of microRNAs had lead to a new era of post-transcriptional regulators of gene expression. Studies from cells, experimental animal models and patients under diabetic conditions demonstrate that expression patterns of microRNAs are altered during the progression of diabetic kidney disease. Functional studies indicate that the ability of microRNAs to bind 3' untranslated region of messenger RNA not only shows their capability to regulate expression of target genes, but also their therapeutic potential to diabetic kidney disease. The presence of microRNAs in plasma, serum, and urine has been shown to be possible biomarkers in diabetic kidney disease. Therefore, identification of the pathogenic role of microRNAs possesses an important clinical impact in terms of prevention and treatment of progression in diabetic kidney disease because it allows us to design novel and specific therapies and diagnostic tools for diabetic kidney disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.